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Mid-term clinical outcomes of new generation drug-eluting stents 
for treatment of diffuse coronary artery disease
Yaygın koroner arter hastalığında yeni kuşak ilaç salınımlı stentlerin
kullanımının orta vadeli klinik sonlanımı
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Objective: Diffuse coronary artery disease (CAD) is a 
challenging issue in clinical cardiology practice. There are 
limited data about percutaneous revascularization in these 
patients.
Methods: This study was an observational clinical evaluation. 
The records of patients with diffuse CAD revascularized with 
new-generation drug-eluting stents (DES) were researched 
retrospectively. Patients treated with multiple, overlapping 
new-generation DES (at least 60mm in length per vessel) 
were included. The incidence of major adverse cardiac events 
(MACE), defined as cardiac death, stent thrombosis, non-fa-
tal myocardial infarction, and target lesion revascularization 
(TLR), at the end of the first year following the index proce-
dure was recorded.
Results: A total of 71 patients (with 75 coronary vessels) 
treated with new-generation DES for diffuse CAD were en-
rolled in the study. Zotarolimus-eluting stents were used in 48 
vessels and biolimus A9-eluting stents were used in 27 ves-
sels. The median total stent length per vessel was 75.0 mm 
(60.0–106.0) and the median number of stents implanted was 
3 (2–4) for each vessel. The cumulative incidence of MACE at 
the end of the first year was 11.2% (8 patients). The presence 
of diabetes mellitus (DM) and ST-segment elevated myocar-
dial infarction (STEMI) were defined as independent clinical 
risk factors related to MACE development.
Conclusion: Coronary artery revascularization with new-gen-
eration drug-eluting stents can be a good choice in the treat-
ment of selected patients with diffuse CAD. DM and STEMI 
were found to be related to poorer clinical outcomes with this 
treatment option in our study.
Amaç: Yaygın koroner arter hastalığı tedavisi klinik kardiyolo-
jinin sıkıntı yaratan durumlarından biridir. Bu hastaların perkü-
tan revaskülarizasyonu ile ilgili veriler sınırlıdır.
Yöntemler: Çalışmamız gözlemsel bir klinik değerlendirme-
dir. Yaygın koroner arter hastalığı olup yeni kuşak ilaç salı-
nımlı stentler (DES) ile revaskülarize edilmiş hastalar geriye 
dönük incelendi. Çoklu, üst üste gelecek şekilde yerleştirilmiş 
yeni kuşak DES’ler (her damar için en az 60 mm uzunlukta 
olacak şekilde) ile tedavi edilmiş hastalar çalışmaya alındı. 
Girişim sonrasındaki ilk yılın sonunda önemli istenmeyen 
kardiyak olay (MACE) sıklığı araştırıldı. MACE kavramı kar-
diyak ölüm, stent trombozu, ölümcül olmayan miyokart en-
farktüsü ve hedef lezyon revaskülarizasyonu ihtiyacı (TLR) 
olarak tanımlandı.
Bulgular: Çalışmaya yaygın koroner arter hastalığı nedeniy-
le yeni kuşak DES’ler ile tedavi edilen 71 hasta (75 koroner 
damar) dahil edildi. Zotarolimus DES 48 koroner damarda, 
biolimus A9 DES 27 koroner damarda kullanıldı. Her koroner 
damar için kullanılan ortalama stent uzunluğu ortalama 75.0 
mm (60.0–106.0) ve yine her damar için kullanılan stent sa-
yısı üç 3 (2–4) olarak bulundu. İlk yıl sonunda toplam MACE 
sıklığı %11.2 olarak izlendi (sekiz hasta). Diabetes mellitus 
ve ST segment yükselmeli miyokart enfarktüsü (STEMI) 
MACE gelişimi ile ilişkili bağımsız klinik risk faktörleri olarak 
belirlendi.
Sonuç: Yaygın koroner arter hastalığında yeni kuşak DES’lerin 
kullanımı ile gerçekleştirilecek koroner arter revaskülarizasyo-
nu seçilmiş olgularda uygun bir seçenek olarak görülmektedir. 
Çalışmamızda diabetes mellitus ve STEMI varlığı bu tedavi 
seçeneğinde olumsuz klinik sonlanım ile ilişkili bulunmuştur.
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ABSTRACT ÖZET
ORIGINAL ARTICLE
Diffuse coronary artery disease (CAD) poses a sig-nificant problem in clinical cardiology practice.
[1] Despite advances in medical treatment and surgical 
revascularization techniques, long-term clinical out-
comes can be suboptimal.[2–4] In past decades, during 
the era of balloon angioplasty and bare metal stents 
(BMS), restenosis and stent thrombosis were fre-
quently seen.[5,6] With the advent of drug-eluting stents 
(DES), interventional cardiologists were able to treat 
longer segments and diffuse coronary lesions.[7,8] How-
ever, we have limited data about the clinical outcomes 
of the treatment approach to diffuse coronary lesions 
using DES that is known as the full metal jacket strat-
egy. The aim of this study was to investigate the effi-
cacy and safety of treatment of diffuse coronary artery 
stenosis with multiple, overlapping DES.
METHODS
Study population
A retrospective search of the hospital database was 
conducted to identify patinets with diffuse coronary 
artery stenosis who were treated with a full metal 
jacket approach. Full metal jacket is defined as a stent 
length ≥60 mm without a gap in a single coronary 
artery.[7] The inclusion criterion for this study was im-
plantation of multiple, overlapping new-generation 
DES, ≥60 mm in total stent length per vessel treated. 
Patients who were treated with a full metal jacket ap-
proach in a single coronary artery and were followed 
up in the cardiology outpatient clinic through the end 
of the first year following the index coronary inter-
vention were included in the present study.
Exclusion criteria were defined according to the 
coronary anatomy and the coronary artery percuta-
neous intervention: 
• BMS implantation (alone or with DES)
• Saphenous vein graft intervention
• Bioabsorbable stent implantation
• Intervention for in-stent restenosis
• DES implantation with former generation plat-
forms
• Patients who were lost to follow-up or did not 
have a clinical non-invasive coronary ischemia 
evaluation in the post-interventional follow-up 
period.
In our center, 2 
kinds of new-gener-
ation DES are used: 
zotarolimus-eluting 
stents (ZES) with 
durable polymers 
(Resolute Integrity, 
Resolute Onyx; 
Medtronic, Inc. 
(Minneapolis, MN, 
USA)) and biolimus 
A9-eluting stents 
(BES) with biode-
gredable polymers 
(Biomatrix Flex; 
Interventional Tech-
nologies Pte Ltd., Singapore). ZES were used exclu-
sively at our center until late 2015; since then, both ZES 
and BES have been in use. The type of stent deployed 
is the choice of the primary operator. Demographic, 
clinical, and angiographic data were collected from the 
hospital database or from patients during clinical visits.
Stenting procedure and angiographic evaluation
Patients with multiple, overlapping DES longer than 
60 mm in length in a single coronary artery were en-
rolled retrospectively and evaluated for major adverse 
cardiac events (MACE). As a general approach, the 
stent diameter and stent length were decided upon after 
repeated dosages of intracoronary nitroglycerin. The 
overlapping areas of the consecutive stents were to be 
2 to 4 mm in length. Chronic total occlusion was de-
fined as a lesion assumed to be occluded more than 3 
months. The decision to perform coronary intervention 
for chronic total occlusion was driven by documenta-
tion of coronary ischemia using myocardial perfusion 
scintigraphy. A bifurcation intervention was defined 
as any side branch greater than 2 mm jailed under the 
stented segment of the main branch. The type of dual 
antiplatelet therapy (DAPT), glycoprotein IIb/IIIa an-
tagonist usage, and postdilatation after stenting were 
decided by the primary operator. In our institution, the 
general approach is postdilatation with non-compliant 
balloons. Angiographic data were evaluated by 2 inde-
pendent cardiologists retrospectively.
Endpoint definition and clinical follow-up
A composite endpoint for MACE was defined as car-
diac death, stent thrombosis (definite or probable), re-
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Abbreviations:
ACS  Acute coronary syndrome
BES  Biolimus A9-eluting stent 
BMS  Bare metal stent 
CAD  Coronary artery disease
CI	 	 Confidence	interval
DAPT  Dual antiplatelet therapy
DES  Drug-eluting stent
DM  Diabetes mellitus
HR  Hazard ratio 
LAD  Left anterior descending artery
MACE	 	 Major	adverse	cardiac	event	
NSTE-ACS	 Non-ST-segment	elevation-acute		
  coronary syndrome 
RCA  Right coronary artery
STEMI	 	 ST-segment	elevation
  myocardial infarction 
TLR	 	 Target	lesion	revascularization
ZES  Zotarolimus-eluting stent
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current myocardial infarction, or target lesion revascu-
larization (TLR). Overall survival was also investigated 
and all deaths were accepted as cardiac death if there 
was no proof of another underlying etiological factor. 
TLR was defined as repeat revascularization via per-
cutaneous intervention or surgically for a previously 
stented area or 5 mm proximal or distal to the stent. 
Routine coronary angiography was not encouraged. A 
TLR designation was based on clinical evidence of is-
chemia. The Third Universal Definition of Myocardial 
Infarction guideline defines perioperative myocardial 
infarction associated with percutaneous coronary in-
tervention as an elevation of cardiac troponin values 
more than 5 times the 99th percentile upper reference 
limit in patients with normal baseline values.[9] Obvi-
ously, diagnosis of myocardial reinfarction may be dif-
ficult in patients with acute coronary syndrome (ACS) 
as a result of the baseline cardiac troponin elevation. 
The Third Universal Definition of Myocardial Infarc-
tion guideline defines myocardial reinfarction as an 
additional >20% increase of cardiac troponin values 
following the peak and decrement curve in ACS pa-
tients.[9] Stent thrombosis was categorized according 
to the Academic Research Consortium definitions.[10]
Statistical analysis
For discrete and continuous variables, descriptive sta-
tistics (mean, SD, median, minimum value, maximum 
value, and percentile) were calculated. In addition, 
the homogeneity of the variances, which is one of the 
prerequisites of parametric tests, was assessed using 
Levene’s test. The assumption of normality was tested 
via the Shapiro-Wilk test. To compare the differences 
between the 2 groups, the Student’s t-test was used 
when the parametric test prerequisites were fulfilled, 
and the Mann-Whitney U test was used when such 
prerequisites were notmet. Cumulative event rates 
were calculated using the Kaplan-Meier method and 
groups were compared with a log-rank test. Risk 
factors were established using the Cochran-Mantel-
Haenszel chi-square test. The data were evaluated us-
ing IBM SPSS Statistics for Windows, Version 20.0 
(IBM Corp., Armonk, NY, USA). P<0.05 and p<0.01 
were used as the levels of significance. 
RESULTS
Demographic and clinical characteristics
A total of 136 patients were treated with multiple, 
overlapping stents longer than >60 mm in length. Six-
ty-five patients were excluded from evaluation due to 
the defined study exclusion criteria: 26 patients with 
earlier DES platforms, 17 patients with BMS+DES, 4 
patients with BMS alone, 2 patients with saphenous 
vein graft intervention, 2 patients with bioabsorbable 
stents, and 2 patients with in-stent restenosis interven-
tion were excluded. Five patients were also excluded 
from the study as a result of loss to follow-up, and 
7 patients were excluded because of the lack of a 
non-invasive coronary ischemia evaluation in the fol-
low-up period. In all, 71 patients (with 75 coronary 
arteries) were ultimately included for MACE evalua-
tion. The demographic and clinical characteristics of 
the patients are provided in Table 1. The mean age of 
the study population was 65 years (39–92 years) and 
73.2% of the study patients were male. The diabetes 
mellitus (DM) frequency in the study population was 
29.6%. Nearly 70% of the patients were admitted with 
an ACS presentation (15.5% unstable angina, 21.1% 
non-ST-segment elevation-acute coronary syndrome 
[NSTE-ACS], 32.4% ST-segment elevation myocar-
dial infarction [STEMI]). Twenty-two cases (31.0%) 
were admitted with stable angina pectoris. 
Angiographical and procedural results
The right coronary artery (RCA) was the vessel most 
often requiring intervention. There were 48 (64.0%) 
RCA and 22 (29.3%) left anterior descending (LAD) 
artery procedures. The chronic total occlusion rate 
was 24% (18 vessels). The rate of bifurcation inter-
vention rate was 41.3% (31 vessels). Ten of these 
31 vessels had undergone kissing ballon dilatation 
(13.3%) and 4 needed 2 stents (5.3%). In our institu-
tion, there is a tendency to perform postdilatation in 
these long segment-stented patients as a routine pro-
cedure, and the postdilatation rate was 94.7% (71 ves-
sels) in this study population. Routine glycoprotein 
IIb/IIIa inhibitor use is not preferred, and in this study 
population, glycoprotein IIb/IIIa inhibitors were used 
in only 7 cases (9.3%). A median of 3 (2–4) stents 
were used for each vessel treated and the median to-
tal stent length per vessel was 75.0 mm (60.0–106.0 
mm). Peri-interventional myocardial infarction diag-
nosed as defined cardiac marker elevation was seen in 
16 interventions (21.3%) (Table 2).
There was a tendency to use more stents per vessel 
and a longer stented segment in the ZES group com-
pared with the BES group, but this difference did not 
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hemorrhage, and the patient was stabilized after a 
blood transfusion. It was not necessary to discontinue 
DAPT for hemorrhagic complications. The peri-in-
terventional myocardial infarction rate was 21.3%, 
which was quite high compared with similar studies, 
but this cardiac marker elevation did not lead to worse 
clinical outcomes.
Clinical outcomes at the end of 1 year
The cumulative incidence of MACE at the end of 1 
year was 11.2% (8 patients). Two patients died within 
the follow-up period (all-cause death rate: 2.8%), 1 of 
which was a cardiac death (cardiac death rate: 1.4%) at 
the fifth month after index coronary intervention. There 
was no significant difference in MACE rate between 
the 2 groups with different types of DES (p=0.387). 
TLR-related MACE had occurred in 3 patients by the 
end of the first year (4% of total study population).
reach statistical significance (Table 3). Furthermore, 
there was no statistically significant difference in the 
mean diameter of the stents implanted between the 
ZES and BES groups.
Peri-interventional complications and in-hospital 
follow-up
There was no instance of in-hospital mortality. All 
of the study patients were discharged in safe clini-
cal condition. One (1.3% of all interventions) case of 
subacute stent thrombosis was observed during the in-
hospital follow-up 36 hours after the index procedure, 
and it was treated successfully with balloon angio-
plasty. In addition, there was 1 case of retroperitoneal 
Table 1. Demographic and clinical characteristics of 
the study population
  Study population
Age (years) 65.0 (39.0–92.0)
Gender-male, n (%)  52 (73.2)
Diabetes mellitus, n (%) 21 (29.6)
Smoking, n (%) 44 (62.0)
Hypertension, n (%) 49 (69.0)
Hyperlipidemia, n (%) 31 (43.7)
Family history of premature
coronary artery disease, n (%) 12 (16.9)
History of previous myocardial
infarction, n (%) 29 (40.8)
History of previous revascularization
(PCI or CABG), n (%) 20 (28.2)
Chronic kidney failure, n (%) 4 (5.6)
Chronic obstructive pulmonary
disease, n (%) 9 (12.7)
Previous TIA or stroke, n (%) 3 (4.2)
Previous peripheral artery
disease, n (%) 5 (7.0)
Admission creatinine (mg/dL) 0.9 (0.6–10.7)
Admission ejection fraction (%) 56.0 (25.0–72.0)
Clinical presentation, n (%)
     Unstable angina pectoris 11 (15.5)
     NSTE-ACS 15  (21.1)
     STEMI 23 (32.4)
     Stable angina pectoris 22 (31.0) 
CABG: Coronary artery bypass graft; NSTE-ACS: Non-ST-segment eleva-
tion-acute coronary syndrome; PCI: Percutaneous coronary intervention; 
RCA: Right coronary artery; STEMI: ST-segment elevation myocardial in-
farction; TIA: Transient ischemic attack.
Table 2. Angiographical data of the study population
  Study population
Target vessel, n (%)
 Right coronary artery 48 (64.0)
 Left anterior descending artery 22 (29.3)
 Circumflex artery 5 (6.7)
SYNTAX score 16.0 (7.0–31.5)
Chronic total occlusion, n (%) 24% (18)
Bifurcation, n (%) 31 (41.3)
Bifurcation intervention ended
with kissing balloon dilatation, n (%) 10 (13.3)
Bifurcation intervention ended
with 2 stents, n (%) 4 (5.3)
Preintervention percentage
of stenosis 99.0 (90.0–100.0)
Predilatation, n (%) 67 (89.3)
Postdilatation, n (%) 71 (94.7)
Glycoprotein IIb/IIIa usage, n (%) 7 (9.3)
Number of stents per vessel 3 (2–4)
Total length of stent per vessel (mm) 75.0 (60.0–106.0)
Mean diameter of stents (mm) 2.83 (2.33–3.25)
Peri-interventional myocardial
infarction, n (%) 16 (21.3)
P2Y12 inhibitor
     Clopidogrel 40 (56.3)
     Ticagrelor 20 (28.1)
     Prasugrel 11 (15.4)
All of the patients enrolled in the study remained 
in follow-up for more than 1 year. The mean length of 
follow-up of the patients enrolled in the study was 18 
months (5–40 months) and at the end of this follow-
up period, the cumulative MACE rate was 13.3% 
(10 patients). TLR-related MACE was experienced 
in only 5 patients (6.7% of total study population) 
at the end of the overall follow-up period (nearly 2 
years). No additional cardiac death or instance of 
stent thrombosis was observed beyond the end of the 
first year.
Various factors thought to potentially be related to 
adverse clinical outcomes were evaluated using the 
Cochran-Mantel-Haenszel chi-square test. The pres-
ence of DM, STEMI, STEMI+NSTE-ACS, age, gen-
der, chronic total occlusion intervention, target ves-
sel (RCA vs. non-RCA), total stent length per vessel, 
number of stents per vessel, mean diameter of stent, 
type of DES and perioperative myocardial infarction 
were used in relation analysis, and after adjustment 
for the study population basal characteristics, DM 
and STEMI were found to be associated with MACE 
development. DM was strongly related with MACE 
occurence (1.9% vs. 30.4%; hazard ratio [HR]: 2.958; 
95% confidence interval [CI]: 0.904–5.012; p=0.005)
(Fig. 1). STEMI presence was also determined to be 
related to adverse clinical outcomes during the fol-
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Table 3. Comparison of zotarolimus and biolimus A9-eluting stent data
 Zotarolimus-eluting stents Biolimus A9-eluting stents p
 Median (Min-Max) Median (Min-Max)
SYNTAX score 15.0 (7.0–31.0) 16.0 (7.0–31.5) 0.858
Number of stents per vessel 3 (2–4) 2 (2–4) 0.112
Total length of stented segment (mm) 78.0 (60.0–100.0) 72.0 (60.0–106.0) 0.147
Mean diameter of stents per vessel (mm) 2.78 (2.33–3.25) 2.87 (2.50–3.00) 0.351
Composite MACE rate at the end of 1 year 4 (8.3%) 4 (14.8%) 0.387
Overall follow-up period (months) 23 (12–40) 13 (5–18) <0.001
MACE: Major adverse cardiac events; Min: Minimum; Max: Maximum.
Figure 1. Effect of presence of diabetes mellitus on the de-
velopment of major adverse cardiac events.
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Figure 2. Effect of presence of ST-segment elevation my-
ocardial infarction on the development of major adverse 
cardiac events.
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stents per lesion and clinical MACE rates. This differ-
ence from previous studies may be related to advanced 
polymer technology, new-generation biodegredable 
polymers (used in Biolimus A9 DES) and new gener-
ation antiplatelet treatment choices. In earlier studies, 
DAPT had been used for 3 to 6 months,[16,17] while in 
our study we aimed to continue DAPT at least for the 
first year following the index procedure. The longer 
duration of DAPT in our study may provide protec-
tion from clinical MACE with respect to stent-related 
factors, such as total stent length, mean stent diame-
ter, and the number of stents per lesion.
DM is a well known clinical risk factor for target 
lesion failure in CAD patients, even those treated with 
new-generation DES.[18] Long-term evaluation of pa-
tients treated with a full metal jacket strategy using 
former generations of DES, DM was found to be an 
independent risk factor for the development of clini-
cal MACE.[19] We found a close relationship between 
presence of DM and clinical MACE rates (1.9% vs. 
30.4%; p=0.005). Although there were few diabetic 
patients in this study, adverse events were seen in al-
most one-third of the diabetic segment of the study 
group within the first year. This high percentage of 
clinical MACE in diabetic patients has prompted con-
cerns about the efficacy of full metal jacket stenting in 
the diabetic population. DM can delay tissue healing 
and endothelization of stent polymers. Overlapping 
stent areas are the most probable points of stent-re-
lated clinical MACE development. Tissue healing 
may be further disturbed at these overlapping sites in 
the presence of DM. Furthermore, impaired glucose 
metabolism and poor diabetic condition have been 
found to be related to increased neointimal prolifer-
ation following DES implantation in animal based 
studies.[20] New-generation antiplatelet agents or a 
longer duration of DAPT may be a solution for better 
clinical outcomes in diabetic patients.
In our study, 52 patients (69.3%) were admitted 
in an ACS setting (STEMI or NSTE-ACS). Only 22 
patients (31.0% of all study population) were admit-
ted to the cardiology outpatient clinic with stable 
angina pectoris. In previous studies, an ACS setting 
was found to be related to a worse clinical MACE rate 
than stable angina pectoris.[21,22] We did not find any 
significant difference in the composite MACE rates 
between ACS and stable angina pectoris patients. 
Although there was a tendency to have more adverse 
low-up period (5.8% vs. 21.7%; HR: 1.629; 95% CI: 
0.048–3.211; p=0.043) (Fig. 2).
DISCUSSION
New-generation DES decreased the prevalance of 
stent restenosis; however, late-term stent thrombo-
sis still remains a question. In theliterature, the total 
length of implanted stents and reference stent diam-
eter were defined as predictors of late stent thrombo-
sis and stent restenosis for DES. In a study evaluating 
the effect of DES length on adverse outcomes during 
clinical follow-up, stent length greater than 31.5 mm 
was found to be related to poorer clinical outcomes, 
including stent thrombosis, death, and myocardial in-
farction.[11] Overlapping areas for multiple, sequential 
DES were also evaluated as high risk regions for ad-
verse clinical outcomes.[12,13] However these studies 
were performed with first-generation DES and we do 
not have enough clinical evidence of the efficacy and 
safety of new-generation DES. Ahn et al.[14] examined 
clinical outcomes of Zotalimus and Sirolimus DES in 
the treatment of long-segment coronary artery disease 
and reported that Zotarolimus DES were determined to 
be non-inferior to the Sirolimus DES and both groups 
had good clinical outcomes. Recently, a study has been 
published that evaluated the MACE rates of long-seg-
ment CAD patients treated with Zotarolimus DES via 
a full metal jacket stenting approach.[15] Researchers 
reported acceptable clinical MACE rates at the end of 
a mean of 3 years of clinical follow-up. However, we 
still do not have enough clinical studies to evaluate the 
effect of new generation DES. In this study, we evalu-
ated the clinical outcomes of patients with diffuse CAD 
treated with Zotarolimus DES and Biolimus A9 DES 
(with biodegradable polymer) via a full metal jacket 
approach. We did not find any difference in composite 
MACE rates between the ZES and BES groups.While 
ZES have been in use longer at our institution, we per-
formed a MACE comparison between these 2 DES at 
the end of 1 year of clinical follow-up.
Previous studies evaluating the efficacy and safety 
of earlier generation DES used in a full metal jacket 
approach found that the total stent length, reference 
stent diameter, and the number of stents (in other 
words, the number of overlapping areas) were related 
to adverse MACE rates in clinical follow-up.[16,17] We 
did not find any significant relationship between total 
stent length, mean stent diameter, or the number of 
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We also examined favorable clinical results in our 
study population, particularly in terms of the low TLR 
rate compared with earlier studies. This improvement 
may be related to advanced stent technology, longer 
DAPT duration, and new-generation antiplatelet 
agents. Zotarolimus and Biolimus A9-eluting stents 
have been introduced to cardiology practice recently.
Conclusion
Our clinical evaluation found that these new genera-
tion DES provide high efficacy and safety. However, a 
full metal jacket stenting approach may still raise con-
cerns for diabetic patients or in patients presenting in 
a STEMI setting. We observed higher MACE results 
at the end of the first year in these 2 patient groups.
Study limitations 
First of all, this is a retrospective clinical study and we 
did not have a control group for comparison of the full 
metal jacket approach to optimal medical treatment or 
to surgical revascularization options. Our study pop-
ulation was also relatively small in size because these 
new-generation DES were introduced to the market 
only recently. The small size of the study group may 
generate difficulties in the evaluation of the statistical 
results about clinical risk factors related to MACE oc-
curence.
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